BRPI1012811A2 - vacinas contra o vírus herpes simplex tipo 2: composições e métodos para obtenção de uma resposta imune - Google Patents

vacinas contra o vírus herpes simplex tipo 2: composições e métodos para obtenção de uma resposta imune

Info

Publication number
BRPI1012811A2
BRPI1012811A2 BRPI1012811A BRPI1012811A BRPI1012811A2 BR PI1012811 A2 BRPI1012811 A2 BR PI1012811A2 BR PI1012811 A BRPI1012811 A BR PI1012811A BR PI1012811 A BRPI1012811 A BR PI1012811A BR PI1012811 A2 BRPI1012811 A2 BR PI1012811A2
Authority
BR
Brazil
Prior art keywords
vaccines
compositions
obtaining
methods
immune response
Prior art date
Application number
BRPI1012811A
Other languages
English (en)
Inventor
Deborah Long
Jessica Flechtner
Mojca Skoberne
Original Assignee
Genocea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genocea Biosciences Inc filed Critical Genocea Biosciences Inc
Publication of BRPI1012811A2 publication Critical patent/BRPI1012811A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI1012811A 2009-05-22 2010-05-24 vacinas contra o vírus herpes simplex tipo 2: composições e métodos para obtenção de uma resposta imune BRPI1012811A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US18078409P 2009-05-22 2009-05-22
US23562809P 2009-08-20 2009-08-20
US24062609P 2009-09-08 2009-09-08
US24058709P 2009-09-08 2009-09-08
US30591810P 2010-02-18 2010-02-18
PCT/US2010/035998 WO2010135747A1 (en) 2009-05-22 2010-05-24 Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Publications (1)

Publication Number Publication Date
BRPI1012811A2 true BRPI1012811A2 (pt) 2016-03-29

Family

ID=43126545

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012811A BRPI1012811A2 (pt) 2009-05-22 2010-05-24 vacinas contra o vírus herpes simplex tipo 2: composições e métodos para obtenção de uma resposta imune

Country Status (17)

Country Link
US (3) US8617564B2 (pt)
EP (3) EP3756684A1 (pt)
JP (2) JP5771605B2 (pt)
KR (1) KR101746872B1 (pt)
CN (2) CN106924728B (pt)
AU (1) AU2010249330B2 (pt)
BR (1) BRPI1012811A2 (pt)
CA (1) CA2797937C (pt)
ES (1) ES2732815T3 (pt)
IL (1) IL216508A (pt)
MX (1) MX2011012347A (pt)
MY (1) MY159500A (pt)
NZ (1) NZ597182A (pt)
RU (1) RU2585961C9 (pt)
SG (1) SG176207A1 (pt)
WO (2) WO2010135749A1 (pt)
ZA (1) ZA201109444B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010249330B2 (en) 2009-05-22 2015-11-05 Genocea Biosciences Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
EP2550289A4 (en) 2010-03-12 2013-11-27 Childrens Medical Center NEW IMMUNOGENES AND METHODS FOR IDENTIFICATION AND SCREENING THEREOF
AU2011336894B2 (en) * 2010-11-24 2016-11-17 Genocea Biosciences, Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
WO2012139099A2 (en) * 2011-04-08 2012-10-11 Duke University Herpes simplex virus vaccine
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
AU2012340712B2 (en) * 2011-11-23 2017-09-14 Genocea Biosciences, Inc. Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
WO2014052971A1 (en) * 2012-09-30 2014-04-03 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsions
CN103074337B (zh) * 2012-12-04 2014-07-09 昆明寰基生物芯片产业有限公司 一段单纯疱疹病毒dna序列及应用
CA2900008C (en) 2013-02-07 2025-10-07 Children's Medical Center Corporation PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE
WO2014164699A1 (en) * 2013-03-11 2014-10-09 The Regents Of The University Of California Herpes virus vaccines and treatments
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
WO2015134368A2 (en) * 2014-03-03 2015-09-11 Albert Einstein College Of Medicine Of Yeshiva University Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
LT3411388T (lt) 2016-02-01 2022-01-10 Simplexia Ab Sutrumpintas herpes simplex viruso 2 glikoproteinas g
KR101962683B1 (ko) * 2016-09-28 2019-03-27 주식회사 에스엘백시젠 Hsv-2 감염 예방 및 치료용 dna 백신
JP2019537555A (ja) * 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド ヘルペスを処置するための方法および組成物
EP3615060A4 (en) 2017-04-26 2021-06-09 Merck Sharp & Dohme Corp. HSV ANTIGEN PEPTIDS AND HSV PROTEIN VACCINES
AU2018316811B2 (en) * 2017-08-17 2023-07-13 The Trustees Of The University Of Pennsylvania Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof
US11213582B2 (en) * 2018-08-08 2022-01-04 The Regents Of The University Of California Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits
TW202019470A (zh) 2018-09-12 2020-06-01 美商艾芬尼維克斯公司 多價肺炎球菌疫苗
BR112021014400A2 (pt) 2019-02-08 2021-09-21 Krystal Biotech, Inc. Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, e, métodos para intensificar, aumentar, elevar e/ou suplementar os níveis de um polipeptídeo cftr em uma ou mais células, para reduzir ou inibir a destruição progressiva do pulmão, para fornecer alívio profilático, paliativo ou terapêutico de um ou mais sinais ou sintomas de fibrose cística e para fornecer alívio profilático, paliativo ou terapêutico de um ou mais sinais ou sintomas de copd
US20240108747A1 (en) 2019-03-21 2024-04-04 Lonza Sales Ag Extracellular vesicle conjugates and uses thereof
BR112021018694A2 (pt) 2019-03-21 2021-11-30 Codiak Biosciences Inc Vesículas extracelulares para distribuição de vacina
CN109943592B (zh) * 2019-04-29 2020-11-17 华中农业大学 含猪伪狂犬病病毒gD蛋白基因的重组杆状病毒转移载体、重组杆状病毒及制备方法和应用
CN110804088A (zh) * 2019-11-18 2020-02-18 维塔恩(广州)医药有限公司 巨细胞病毒相关抗原短肽及其应用
CN110724181A (zh) * 2019-11-18 2020-01-24 维塔恩(广州)医药有限公司 单纯疱疹病毒相关抗原短肽及其应用
CN110746497A (zh) * 2019-11-18 2020-02-04 维塔恩(广州)医药有限公司 肺炎衣原体相关抗原短肽及其应用
CN110845583A (zh) * 2019-11-18 2020-02-28 维塔恩(广州)医药有限公司 水痘带状疱疹病毒相关抗原短肽及其应用
CA3213789A1 (en) 2021-04-02 2022-10-06 Krystal Biotech, Inc. Viral vectors for cancer therapy
WO2023039223A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818694A (en) * 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
US7264817B1 (en) * 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5612041A (en) * 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
WO1990013652A1 (en) * 1989-05-12 1990-11-15 Triton Diagnostics, Inc. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
JP3005292B2 (ja) * 1990-08-02 2000-01-31 カイロン コーポレイション 単純ヘルペスウィルスのｖｐ１６のワクチン
DK31991D0 (da) * 1991-02-25 1991-02-25 Carlbiotech Ltd As Peptid og farmaceutisk praeparat indeholdende et saadant peptid
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5679348A (en) 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
JPH08510918A (ja) 1993-06-08 1996-11-19 アボツト・ラボラトリーズ 単純ヘルペスウィルス２型プロテアーゼ
CA2169748A1 (en) 1993-08-20 1995-03-02 Anthony G. Dilella Hsv-2 ul26 gene, capsid proteins, immunoassays and protease inhibitors
GB9325496D0 (en) * 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
US7094767B2 (en) * 1994-07-22 2006-08-22 Merck & Co., Inc. Polynucleotide herpes virus vaccine
US6156319A (en) * 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
US5807557A (en) 1994-07-25 1998-09-15 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US6197497B1 (en) * 1995-04-21 2001-03-06 University Of New Mexico Immunoassay for herpes simplex virus
US5654174A (en) * 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
US5876923A (en) 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
CA2269754A1 (en) * 1996-10-23 1998-04-30 American Home Products Corporation Dna vaccines for herpes simplex virus 1 and 2
CN1324139C (zh) * 1996-10-23 2007-07-04 惠氏 疫苗
EP0948508A4 (en) 1996-11-04 2001-11-07 Smithkline Beecham Corp NEW CODING SEQUENCES FOR HERPES SIMPLEX TYPE 2 VIRUS
US6218103B1 (en) * 1997-04-16 2001-04-17 Arch Development Corporation Herpes simplex virus US3 and ICP4 as inhibitors of apoptosis
AU7597998A (en) 1997-06-02 1998-12-21 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6054131A (en) * 1998-01-16 2000-04-25 University Of Maryland Baltimore Vaccine composition for herpes simplex virus and method of using
ES2273482T3 (es) * 1998-03-09 2007-05-01 Glaxosmithkline Biologicals S.A. Composiciones de vacunas combinadas.
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
JP2002522451A (ja) * 1998-08-07 2002-07-23 ユニバーシティ オブ ワシントン 免疫学的単純ヘルペスウイルス抗原とその使用法
US6692752B1 (en) * 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
EP1185662B1 (fr) 1999-06-10 2011-03-02 Merial Vaccins adn pour les chiens
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6413518B1 (en) * 1999-09-30 2002-07-02 University Of Washington Immunologically significant herpes simplex virus antigens and methods for identifying and using same
US7196066B1 (en) * 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
DK1238086T3 (da) * 1999-12-17 2006-06-26 Wyeth Corp Vaccine til forögelse af immunreaktioner på herpes simplex virus
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
US7157437B2 (en) * 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
ATE349533T1 (de) * 2000-06-29 2007-01-15 Corixa Corp Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen
US20030165819A1 (en) * 2000-06-29 2003-09-04 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6682892B2 (en) * 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
JP2004505113A (ja) * 2000-07-27 2004-02-19 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 単純疱疹ウイルス糖蛋白質ｄを用いた組成物及びそれを用いて免疫応答を抑制する方法
EP1178111A1 (en) 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
US20020094337A1 (en) * 2000-11-16 2002-07-18 University Of Maryland, Baltimore Prevention of recurrent viral disease
US6867000B2 (en) * 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
EP2545937A1 (en) 2001-06-05 2013-01-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
US6814969B2 (en) * 2001-07-31 2004-11-09 University Of Washington Immunologically significant herpes simplex virus antigens and methods for using same
AU2002323443A1 (en) 2001-09-04 2003-03-18 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20030219448A1 (en) * 2002-05-24 2003-11-27 Cedars-Sinai Medical Center Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases
US20080299140A1 (en) * 2002-05-24 2008-12-04 The Regents Of The University Of California, Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition
DK2011510T3 (da) * 2002-07-18 2011-03-28 Univ Washington Farmaceutiske sammensætninger indeholdende immunologisk aktive Herpes simplex-virus(HSV) proteinfragmenter
US7267940B2 (en) * 2003-03-04 2007-09-11 Bio-Rad Laboratories, Inc. HSV-2 type-specific immunoassays using glycoprotein G2 peptides
AU2004274430A1 (en) * 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
AU2006338570B2 (en) * 2005-11-18 2013-07-11 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
CA2645507A1 (en) 2006-03-10 2007-09-20 The Regents Of The University Of California Vaccine for viruses that cause persistent or latent infections
EP2521786B1 (en) 2006-07-20 2015-06-24 Vical Incorporated Compositions for vaccinating against hsv-2
WO2008027394A2 (en) 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
CA2663109A1 (en) * 2006-09-08 2008-03-13 The Trustees Of The University Of Pennsylvania Hsv-1 and hsv-2 vaccines and methods of use thereof
EP2087128A4 (en) 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
US9284355B2 (en) * 2006-12-28 2016-03-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US8057804B2 (en) * 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2009006618A2 (en) 2007-07-05 2009-01-08 University Of Kansas Herpes simplex virus mutant icp0 protein
WO2009006680A1 (en) 2007-07-06 2009-01-15 Sydney West Area Health Service Epitopes of herpes simplex virus
EP2293814A4 (en) * 2008-05-23 2013-02-13 Univ Michigan NANOEMULSION AGENTS
SE532551C2 (sv) 2008-06-30 2010-02-16 Senseair Ab Ett för spektralanalys anpassat arrangemang
US8313894B2 (en) 2008-07-01 2012-11-20 Genocea Biosciences, Inc. Antigen screening system
WO2010078027A1 (en) 2008-12-17 2010-07-08 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
US8460674B2 (en) * 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
CA2754592A1 (en) 2009-03-09 2010-09-16 William Henry Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions
AU2010249330B2 (en) 2009-05-22 2015-11-05 Genocea Biosciences Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
US9089537B2 (en) 2010-02-26 2015-07-28 The Trustees Of The University Of Pennslyvania Subunit vaccines for herpes viruses and methods of use
US20130195961A1 (en) 2010-03-09 2013-08-01 Kejian Yang Novel mucosal vaccination approach for herpes simplex virus type-2
CA2849391A1 (en) 2010-10-20 2012-04-26 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
AU2011336894B2 (en) 2010-11-24 2016-11-17 Genocea Biosciences, Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
AU2012340712B2 (en) 2011-11-23 2017-09-14 Genocea Biosciences, Inc. Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド ヘルペスを処置するための方法および組成物

Also Published As

Publication number Publication date
EP2432504B1 (en) 2019-05-01
CN106924728B (zh) 2021-02-05
IL216508A0 (en) 2012-02-29
IL216508A (en) 2016-08-31
US8617564B2 (en) 2013-12-31
WO2010135749A1 (en) 2010-11-25
WO2010135747A1 (en) 2010-11-25
US20180369365A1 (en) 2018-12-27
WO2010135749A9 (en) 2011-07-21
EP3756684A1 (en) 2020-12-30
ES2732815T3 (es) 2019-11-26
RU2585961C2 (ru) 2016-06-10
EP3590533A1 (en) 2020-01-08
AU2010249330B2 (en) 2015-11-05
CN102458463B (zh) 2017-01-18
RU2585961C9 (ru) 2016-12-27
US10653771B2 (en) 2020-05-19
JP5771605B2 (ja) 2015-09-02
US9895436B2 (en) 2018-02-20
KR101746872B1 (ko) 2017-06-14
CA2797937C (en) 2020-01-14
JP2015178529A (ja) 2015-10-08
EP2432504A1 (en) 2012-03-28
KR20120087805A (ko) 2012-08-07
NZ597182A (en) 2014-07-25
MY159500A (en) 2017-01-13
MX2011012347A (es) 2012-02-21
JP2012527486A (ja) 2012-11-08
ZA201109444B (en) 2016-09-28
CA2797937A1 (en) 2010-11-25
CN102458463A (zh) 2012-05-16
EP2432504A4 (en) 2013-07-31
SG176207A1 (en) 2011-12-29
JP6096839B2 (ja) 2017-03-15
CN106924728A (zh) 2017-07-07
RU2011147153A (ru) 2013-06-27
AU2010249330A1 (en) 2012-01-19
US20100330112A1 (en) 2010-12-30
US20140227307A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
BRPI1012811A2 (pt) vacinas contra o vírus herpes simplex tipo 2: composições e métodos para obtenção de uma resposta imune
HUE039747T2 (hu) Eljárások és kompozíciók EGFRVIII-ra való immunválasz indukálására
BRPI0920283A2 (pt) composição e método para induzir resposta imunológica humoral
BR112012019757A2 (pt) composição imunogênica, e, método para induzir uma resposta imune a um polissacarídeo capsular
IL215430A (en) Immunogenic compositions and vaccines for immunization against viruses and use thereof
BRPI0908348A2 (pt) Métodos e kits de composições para acentuar a resposta imunológica a uma condição respiratória
EP2069376A4 (en) INDUCTION OF CELLULAR IMMUNE RESPONSES TO INFLUENZA VIRUS BY COMPOSITIONS OF PEPTIDES AND NUCLEIC ACIDS
ZA201307394B (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
DK3170508T3 (da) Vaccineformuleringer
HUE031343T2 (hu) Immunitásindukáló ágens
PT2658570T (pt) Composições e métodos vacinais contra o vírus da diarreia viral bovina tipo 1b
IL261562A (en) Preparations containing decitabine derivatives and their uses
BRPI1011902A2 (pt) composições e métodos para potencialização de respostas imunes antígeno-específicas
EP2387416A4 (en) PURIFIED PLASMODIUM AND VACCINE COMPOSITIONS
EP2516629A4 (en) VACCINES AGAINST HERPES SIMPLEX VIRUS
BRPI1007721A2 (pt) composição de vacina para induzir uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolada e método para induzir uma resposta imunológica para um rotavírus em um indivíduo
DK2909334T3 (da) Gensignaturer af inflammatoriske lidelser, som er relateret til leveren og Crohns sygdom
EP2825196A4 (en) ADJUVANZ AND VACCINE COMPOSITIONS
GB201005625D0 (en) Immunogenic proteins and compositions
EP2484378A4 (en) HEPATITIS C VIRUS VACCINE COMPOSITION
GB201003333D0 (en) Immunogenic proteins and compositions
BRPI0820258A2 (pt) composto, composições de vacina e farmacêutica, e , métodos para estimular uma resposta imune em um indivíduo e para tratar um indivíduo
EP2643014A4 (en) HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
ZA201003964B (en) Compositions for and methods of enhancing the immune response to antigens
EP2747779A4 (en) HERPES SIMPLEX VIRUS VACCINE NANOEMULSION

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2724 DE 21/03/2023.